1. Whole Parasite Vaccines {#sec1}
==========================

1.1. Preerythrocytic Stages {#sec1.1}
---------------------------

The seminal work using radiation-attenuated sporozoites has been reproduced in multiple experimental systems, demonstrating that attenuated infective forms of *Plasmodium sp.* administered by the endovenous route can provide solid vaccination status against any symptoms of malaria \[[@B1]\]. However, the use of radiation-attenuated, viable live sporozoites imposes a number of restrictions because if the radiation fails, then these parasites would cause the disease, thereby nullifying any protective effects. To definitively solve this problem, a number of genetically attenuated lines of parasites have been recently generated. These genetically attenuated parasites are now being pursued as possible antigenic sources for vaccine development for humans, and Phase I and II studies are about to begin \[[@B2]--[@B5]\].

1.2. Erythrocytic Stages {#sec1.2}
------------------------

Likewise, genetically attenuated blood-stage forms of rodent malaria parasites have been successfully generated in the past few years and have been proposed as an antigen source for human vaccination trials \[[@B5]--[@B7]\]. To our knowledge, none of these parasite lines are being tested in Phase I or II trials. Although it is technically feasible to produce large amounts of genetically attenuated sporozoites or blood-stage forms, it would be difficult to commercialise these vaccines because the parasites would have to be injected live (cryopreserved) by the endovenous route to confer protective immunity. There are also safety issues related to intravenous injections of these formulations because vaccines are not conventionally administered by this route. These two issues will certainly become the main obstacles that must be overcome for successful whole parasite vaccine development.

2. Recombinant Subunit Vaccines {#sec2}
===============================

The difficulties associated with large-scale generation of whole parasite antigens for mass vaccination led to the search for recombinant subunit vaccines based on immunodominant malarial antigens. Again, the mouse malaria model was very instructive for narrowing the search for the most promising antigens and testing different recombinant formulations, which provided the proof of principle for these subunit recombinant vaccines. Based on many years of detailed studies, some leading candidate antigens and formulations for vaccines were selected and exhaustively tested, but these tests have mainly occurred in the mouse model of infection as well as nonhuman primates.

2.1. Preerythrocytic Stages {#sec2.1}
---------------------------

Immunity generated by radiation-attenuated sporozoites is targeted to a dominant protective antigen, the circumsporozoite (CS) protein \[[@B8]\]. Nevertheless, other protective antigens yet to be characterized do exist \[[@B8], [@B9]\]. This protein is recognized by antibodies, CD4^+^ and CD8^+^T cells induced by immunisation with radiation-attenuated sporozoites that can eliminate the pre-erythrocytic stages of the parasite \[[@B10]--[@B14]\]. These results led to the development of vaccine formulations that elicit high antibody titres against sporozoites and/or increased numbers of CD4^+^ and CD8^+^ T cells specific for malaria liver stages. Although other proteins such as Liver Stage 1 or 3 and Thrombospondin-Related Anonymous Protein (TRAP) are also being explored as vaccine candidates, the CS protein can be used as a prototypical example of a pre-erythrocytic stage antigen, and the results can be extrapolated to the other surface antigens.

High antibody titres can be achieved, for example, using multiple synthetic peptides (MAPs) formulated in the presence of strong adjuvants \[[@B15]--[@B17]\]. Because of the success in rodent models, human safety and efficacy trials are warranted.

The most reliable and reproducible results of vaccination against pre-erythrocytic stages in rodent malaria models were obtained by vaccination with two recombinant viral vectors. Using attenuated viruses containing the entire CS protein or its immunodominant epitopes, a solid and long-lasting protective immunity against sporozoite challenge was elicited \[[@B18]--[@B20]\]. Although some protocols managed to use only a single vector for vaccination \[[@B21]\], heterologous prime-boost vaccination using two different vectors for priming and boosting may be essential for eliciting protective immunity \[[@B22]--[@B25]\].

These exciting results obtained in the mouse model led to a number of clinical trials. Unfortunately, these trials provided only limited protective immunity in Phase II trials performed in the laboratory, and none in the field \[[@B26]--[@B28]\]. The reasons for such failures are difficult to explain precisely. The failures may be related to low antibody levels and/or fewer specific CD4^+^ and CD8^+^ T cells generated by these recombinant viruses in humans compared to mice. Based on the mouse model, relatively large amounts of CD4^+^ and CD8^+^ T cells are required for complete protective immunity because high numbers of these cells are already required to patrol the entire liver \[[@B13], [@B18], [@B19], [@B29], [@B30]\]. More powerful viral vectors and strategies of vaccination are being developed every day, and future approaches may increase the number of these protective T cells. Nevertheless, it is unclear whether it will ever be possible to reproduce in humans the levels of immunity induced by viral vectors that are found in the mouse models.

Despite the great progress in malaria vaccine research against pre-erythrocytic stages in the past 20 years, a single type of formulation has shown promising results when tested in humans. This vaccine formulation consists of a large C-terminal fragment of the CS protein sequence fused to the Hepatitis B antigen S (conventional hepatitis B vaccine, Engerix B) and expressed as a recombinant protein in *Saccharomyces cerevisiae*. The fusion protein, named RTS, when expressed together with antigen S, naturally assembles into virus-like particles called RTS,S. The efficacy of the RTS,S formulation is dependent on the use of adjuvant systems (AS), which consist of two different formulations that include monophosphoryl lipid A (MPL, a detoxified form of LPS) and QS21 (saponin purified from *Quillaja saponaria*) in an oil-in-water emulsion (AS02) or in a liposomal suspension (AS01) \[[@B31]\].

In recent Phase II trials performed in naïve human volunteers challenged with *P. falciparum* sporozoites, efficacies ranging from 32% to 50% were observed. Immunological studies performed on these vaccinated individuals indicated that protection correlated with the concentration of specific antibodies and the frequency of IFN-*γ* producing cells as detected by ELISPOT \[[@B32]\]. A number of Phase IIb trials have been carried out, and they continue to be carried out in the field. These results are more difficult to interpret, but in trials performed in children in the endemic areas, 49.5% and 62% efficacy were reported during the 6-month period that was studied retarding the first malaria episode \[[@B33], [@B34]\]. Although partial, the protective immunity afforded by this vaccination protocol can be considered the most hopeful path for vaccine development to date. Because protective immunity was highly dependent on the adjuvants used in the formulation, these studies highlighted the importance of adjuvant development for a reliable malaria vaccine (see below). Currently, this formulation is being tested in Phase III trials in malaria-endemic areas, and the results are anxiously expected for the years 2011-12 \[[@B31]\].

2.2. Erythrocytic Stages {#sec2.2}
------------------------

The erythrocytic forms of malaria grow and multiply within the host erythrocytes, and the rupture of the host cells is responsible for the clinical symptoms, including fever, of the noncomplicated forms of the disease. Nevertheless, infected erythrocytes (iEs) can also cytoadhere by means of variant surface antigens (VSA) to endothelial receptors on the microvasculature of certain organs or to the placental trophoblast, thereby disappearing from peripheral blood circulation. This phenomenon, named sequestration, is responsible for the majority of the deaths caused by malaria because it leads to the severe forms of malaria, including cerebral malaria, severe anaemia, acute respiratory distress symptoms or pregnancy-associated malaria (PAM) \[[@B35]\]. Because blood-stage forms of the parasite are responsible for the clinical manifestations of the disease, a vaccine against them would prevent or reduce the morbidity and mortality of malaria through the elimination or reduction of the parasitic burden (reviewed in \[[@B36], [@B37]\]).

In the case of PAM, the scenario is complex because cytoadherence is mediated by VSA. Given that *P. falciparum*erythrocyte membrane protein-1 (PfEMP-1) is involved on parasite cytoadhesion and several studies indicate that PfEMP-1 is the major target during natural acquired immunity, this protein family is the only VSA under consideration for vaccine development based on the induction of adhesion-blocking antibodies (reviewed in \[[@B38]\]). Furthermore, because PAM is associated with a selection of antigenically distinct iEs that express a particular PfEMP-1 variant named VAR2CSA, a specific vaccine against this syndrome, based on this variant, should also be developed \[[@B35]\]. Several bodies of evidence point the VAR2CSA protein as a leading vaccine candidate against PAM and strategies based on induction of antibodies capable of inhibiting the adhesion of iEs to chondroitin sulphate A (CSA) in the placenta have recently been pursued \[[@B38], [@B39]\]. In fact, disruption of *var2csa* gene abrogates iEs CSA binding ability, plasma antibody levels against VAR2CSA are gender-specific, and naturally acquisition of high levels of VAR2CSA specific antibodies is parity-dependent and correlates to protection against PAM. However, large-scale development of a full-length VAR2CSA recombinant protein is hampered by its size (350 kDa). An alternative is the expression of all or some of its six Duffy binding-like (DBL) domains, although full-length VAR2CSA displays higher specificity and affinity to human CSA and induced antibodies abrogate adhesion of iEs to CSA \[[@B40]\]. Nevertheless, detailed characterization regarding VAR2CSA DBL domains interaction with CSA backbone, the resolution of their molecular structure (individually or as large fragments), and their involvement in PAM are still puzzling \[[@B38], [@B39]\].

Concerning blood-stage antigens of *Plasmodium* not directly related to PAM, in the last 20 years significant progress has been made in their molecular characterisation as well as in the identification of the immunologic mechanisms capable of eliminating these forms of the parasite (reviewed in \[[@B41]--[@B43]\]). Among the immunodominant antigens already characterised from blood-stage parasites, one of the main candidates for the development of a vaccine against *Plasmodium* is the Merozoite Surface Protein 1 (MSP-1) (revised in \[[@B44]\]). Although other proteins, such as Apical Membrane Antigen 1 (AMA-1) and Duffy-Binding Protein (DBP), are also being explored as vaccine candidates (revised in \[[@B45]--[@B47]\]), MSP-1 can be used as a prototypical example of a blood-stage antigen, and the results obtained from a vaccine developed around this antigen can be extrapolated to other surface antigens.

In different species of *Plasmodium,* the structure of the C-terminal region of MSP-1 (MSP1~19~) consists of two domains. These domains contain 10--12 cysteine residues. Domain 1 or 2 contain 4--6 or 6 cysteine residues and form 2-3 or 3 disulphide bonds, respectively. Both domains are configured as epidermal growth factor-(EGF-) like domains. This type of conformation was initially suggested by the primary amino acid structure and was later confirmed by the three-dimensional analysis of recombinant proteins representing the MSP1~19~ regions of *P. cynomolgi* and *P. falciparum*. The structure of the MSP1~19~ of *P. vivax* (PvMSP1~19~) was recently elucidated through NMR, and it corroborated the MSP1~19~ structures previously described in other species \[[@B48]\].

During invasion of the host erythrocytes, MSP-1 is a target of proteolytic processes. Various studies have demonstrated that MSP1~42~ is found as a dimer, while MSP1~19~ remains monomeric, suggesting a secondary process that would cause the dissociation of the protein before the erythrocytes are invaded (reviewed in \[[@B44]\]).

The precise biological role of MSP-1 is still unknown. However, several studies have demonstrated that antibodies specific for the MSP1~19~ of *P. falciparum*(PfMSP1~19~) can inhibit the invasion of merozoites, suggesting that this protein is involved in the process of erythrocyte invasion. In this context, attempts to knock down the coding genes of six merozoite proteins of *P. falciparum* associated with the membrane through the GPI anchor (MSP-1, MSP-2, MSP-4, MSP-5, MSP-10, RAMA, and Pf92) demonstrated that successful genetic deletion could not be obtained, with the exception of the *msp-5* gene. These observations highlight the importance of these proteins in the blood cycle of the malaria parasite \[[@B49], [@B50]\]. Finally, developmental knockout proved the importance of MSP-1 in the structure of *Plasmodium* merozoites \[[@B51]\].

Based on these positive attributes, the C-terminal region of MSP-1 (MSP1~19~ or MSP1~42~) has been heavily pursued as a vaccine candidate. Initial studies in mouse models demonstrated solid levels of protective immunity after vaccination with strong adjuvants, such as Complete Freund\'s Adjuvant \[[@B52], [@B53]\]. Other adjuvants did not elicit a similar effect, which clearly demonstrates the importance of the adjuvant in vaccine formulations. Although protective immunity is mostly mediated by antibodies, a recent study showed that the presence of CD4^+^ T helper epitopes improves the protective immunity induced in mouse models \[[@B54]\]. Subsequent studies performed in nonhuman primates duplicated these results by demonstrating a strict requirement for a strong adjuvant (e.g., Complete Freund\'s Adjuvant) to stimulate protective immunity against experimental infection with *P. cynomolgi* or *P. falciparum* \[[@B55], [@B56]\].

Based on the results obtained from the experimental models of malaria infection, a recent Phase IIb vaccine trial was performed in Africa. In this clinical trial, children were vaccinated with a formulation containing a recombinant His-tagged fusion protein encompassing the MSP1~42~ of the *P. falciparum*3D7 strain (FMP1) that was formulated with the adjuvant AS02 \[[@B57]\]. This vaccine formulation was shown to be safe and immunogenic, as demonstrated by detection of specific antibody titres by ELISA. Unfortunately, the trial failed, and no significant reduction in the incidence of malaria infection could be observed in children receiving the FMP1/AS02 formulation \[[@B57]\]. The precise reason why the vaccination failed should be investigated. It might be attributed to a polymorphism of the MSP-1 protein. This fact may be relevant to the interpretation of the results because protective immunity to the C-terminal region of *P. falciparum* MSP-1 can be strain-specific, and antibodies targeting this antigen may not show parasite inhibitory activity \[[@B56]\]. Furthermore, some of the MSP-1-specific antibodies are endowed with the ability to block the activity of inhibitory antibodies \[[@B44]\]. Although negative, these results do not completely refute the hypothesis that the C-terminal region of *P. falciparum* MSP-1 could be part of a subunit malaria vaccine in a new recombinant form or formulation. Currently, the immunogenic properties of distinct recombinant proteins are being compared in experimental animal models to select possible candidates for human trials \[[@B58]\].

3. Bacterial Flagellin Fusion Proteins: Bridging the Gap between Mice and Humans? {#sec3}
=================================================================================

As thoroughly discussed above, vaccination of mice with recombinant proteins or viral vectors may confer significant protection against an infectious challenge with malaria parasites. The main problem is that some of these formulations, such as the ones containing strong adjuvants, simply cannot be used in humans. Others, such as the recombinant viruses, failed to reproduce in humans the immunogenicity observed in mice. These successive failures have led to the search for new alternatives that could eventually bridge the gap between mice and humans.

3.1. Bacterial Flagellins {#sec3.1}
-------------------------

Flagella represent a complex locomotion device expressed by different bacterial species. They encompass at least 50 different proteins. Flagella may also behave as virulence-associated factors by helping pathogenic bacteria to bind to epithelial cells and to overcome non-immune defence mechanisms such as liquid flow in the urinary tract. Flagellin, the structural protein of the flagellar filament, is the most abundant protein of the flagellar apparatus, which can assemble by the polymerisation of thousands of flagellin monomers. The molecular masses of flagellins can vary from 28 kDa to 80 kDa. The N- and C-terminal regions of these molecules are highly conserved among different bacterial species and are folded together in parallel as a packed *α*-helix structure that is recognised by innate receptors of the immune system (see below). On the other hand, the central region shows a striking degree of sequence heterogeneity, even among flagellins from a single bacterial species. This heterogeneity has been observed in *Salmonella enterica* serovars, an immune escape mechanism reflecting the fact that most B cell epitopes are exposed to this region of the molecule \[[@B59]\].

Flagellin is a Pathogen-Associated Molecular Pattern (PAMP) recognised by Pattern Recognition Receptors (PRRs) in the innate immune system that triggers inflammatory responses and activates the adaptative immune system. At least two classes of PRRs, Toll-like Receptors (TLRs) and NOD-like Receptors (NLRs), respond to flagellin.

TLR5 is a transmembrane receptor with a conserved cytoplasmic signalling domain---the Toll/interleukin (IL)-1 receptor homology domain (TIR), a common signature for TLRs---that specifically recognises a conserved site in the N- and C-terminal regions of flagellin that is formed after the correct assembly of the molecule; in fact, this site is essential for the correct flagella assembly \[[@B60], [@B61]\]. The receptor is expressed by monocytes, dendritic cells (DCs), and epithelial cells that sense extracellular flagellin. When activated, TLR5 signals through the adaptor protein MyD88 to trigger NF-*κ*B activation and the subsequent expression of proinflammatory cytokines. Flagellin also induces the expression of a number of activation markers in antigen-presenting cells (APCs), such as CD80, CD86, CD40, and MHC class II, all of which augment antigen presentation to T cells \[[@B62]--[@B67]\]. Interestingly, flagellin is one of the two proteic agonist of TLRs.

In the case of the NLRs, flagellin that is expressed by intracellularly replicating pathogens or specifically injected by a secretory apparatus displayed by some bacterial pathogens, such as *S. enterica*, activates a multiprotein cytosolic complex, the inflammasome, which is involved in the regulation of inflammation and cell death responses in a manner dependent on ICE-protease-activating factor (Ipaf) and neuronal apoptosis inhibitory protein 5 (Naip5) \[[@B68], [@B69]\]. Activation of the inflammasome by cytosolic flagellin is related to the control of bacterial growth \[[@B70], [@B71]\] and triggers Caspase-1 activation followed by proinflammatory cell death (pyroptosis) with secretion of IL-1*β* and IL-18 and activation of inducible nitric-oxide synthase, iNOS \[[@B68], [@B72], [@B73]\]. A short C-terminal region of flagellin, which is distinct from the sequences required for TLR5 activation, is responsible for Naip5/Ipaf-containing inflammasome activation \[[@B69]\]. Nevertheless, it remains elusive whether flagellin binds directly to Naip5 or Ipaf or if it acts through an undefined upstream receptor.

Clearly, mammalian cells evolved the ability to very efficiently sense the presence of extra- and intracellular flagellins and respond with strong inflammatory signals that may ultimately enhance the induction of adaptive immune defences. Based on these natural properties, bacterial flagellins have been intensively investigated as vaccine adjuvants that can either be co-administered with purified recombinant antigens or as a carrier/adjuvant molecule genetically fused to the target antigen.

3.2. Bacterial Flagellins As Vaccine Adjuvants {#sec3.2}
----------------------------------------------

In the late 80s, a seminal work envisaged the use of bacterial flagellins as carriers/adjuvants for vaccine antigens by cloning synthetic oligonucleotides encoding specific B or T-cell epitopes at the central hypervariable region of the *S.* Muenchen FliC*d* flagellin expressed in an attenuated *S*. Dublin vaccine strain that was delivered via mucosal or parenteral routes to mice \[[@B74]\]. Purified recombinant forms of flagellin genetically fused to short synthetic oligonucleotides were also successfully used as subunit vaccines by targeting either influenza virus haemagglutinin or an adhesin expressed by enterotoxigenic *Escherichia coli* strains even before the discovery that flagellin activates innate immune responses \[[@B75], [@B76]\].

More recently, the description of innate immune receptors that recognise flagellin and their capacity to activate innate and adaptive immune responses intensified the studies testing bacterial flagellins as vaccine adjuvants for the induction of both antibody and cellular immune responses. Different systems that used flagellins as carriers/adjuvants for recombinant fusion proteins or with coadministered recombinant antigens were tested in the last few years; for a detailed and updated compilation of these data, we recommend a very recently published paper \[[@B77]\].

For brevity and the purpose of our review, we selected the vaccine field that is highly advanced: the development of an anti-influenza vaccine. Two formulations of fusion proteins of flagellin and influenza antigen were generated. First, four tandem copies of the ectodomain of the conserved matrix protein M2 (M2e) of human influenza A virus were fused to the C-terminal domain of the flagellin of *Salmonella typhimurium*fljB (Type 2). A second formulation was generated by the fusion of the viral haemagglutinin globular head domain to the C-terminus of flagellin or in place of the D3 domain (VAX125). All proteins were expressed as soluble fusion proteins in the *E. coli* system. The preclinical studies testing these vaccines reported induction of strong humoral-specific immune responses against the influenza antigens after immunisation of mice and rabbits with the recombinant fusion proteins alone. In both cases, the antibody response was dependent on the physical fusion of the antigen to the flagellin. Most relevant for vaccination studies was the fact that immunisation with either construct protected mice from a lethal challenge with influenza A virus and significantly reduced weight loss and clinical symptoms compared to control animals \[[@B78], [@B79]\].

Based on these successful pre-clinical studies, the influenza vaccine candidate VAX125 underwent a complete Phase I clinical trial that tested safety, reactogenicity, immunogenicity, tolerogenicity, and escalating dose-range. The results from this trial showed that recombinant flagellin was generally well tolerated by vaccinated individuals. Importantly, 91% of the individuals who received any dose of recombinant protein developed titres of neutralising antibodies compatible with protective status against influenza infection (<http://clinicaltrials.gov/NCT00921947/>) \[[@B80]\].

3.3. Bacterial Flagellin As a Carrier/Adjuvant for Malaria Antigens {#sec3.3}
-------------------------------------------------------------------

Based on the great capacity of flagellin to induce humoral and cellular immune responses against foreign antigens, we explored the use of this molecule for the generation of fusion proteins containing malarial antigens. We selected for our initial studies the 19-kDa C-terminal region of MSP-1 from *P. vivax.*This region of MSP-1, termed PvMSP1~19~, was selected because it is arguably the most immunogenic region of *P. vivax* \[[@B81]\]. In immuno-epidemiological studies performed all around the world, this molecule has been shown to be highly conserved \[[@B82]\] and recognised by more than 95% of individuals after their first contact with the *P. vivax* \[[@B83]\]. Most pertinent for vaccine development, immunisation of nonhuman primates with a recombinant protein based on PvMSP1~19~ resulted in protection against an experimental challenge \[[@B84]\].

PvMSP1~19~ was fused to the C-terminal end of the FliC flagellin from *S. typhimurium*. This fusion protein was able to bind and activate TLR5 that was expressed by *in vitro* cultured transfected cells, and it was recognised by serum from *P. vivax* malaria patients. Moreover, the fusion protein was recognised by monoclonal antibodies directed against the three-dimensional structural epitopes, indicating that it was correctly folded when expressed in the *E. coli* system \[[@B85]\].

We immunised mice and rabbits with the recombinant fusion protein in the absence of any other adjuvant. Immunised animals developed strong, specific, and long-lasting antibody-mediated responses. The antibody titres after the second dose were similar to the ones obtained following immunisation with a recombinant protein containing only the PvMSP1~19~ emulsified in Complete/Incomplete Freund\'s Adjuvant. Additionally, the antibodies raised after these immunisations recognised *P. vivax* merozoites by immunofluorescence \[[@B85]\].

In the absence of any other adjuvant, the pattern of the immune response was biased toward a type 2 response, with a high IgG1/2 ratio and limited amounts of IFN-*γ* secreted by the splenic immune cells. Nevertheless, the addition of other adjuvants to the fusion protein, such as TLR-9 agonist, modulated the immune response towards a type 1 response, with a lower IgG1/2 ratio and secretion of significantly more IFN-*γ* \[[@B85]\].

Because long-term *in vitro* culture of *P. vivax* is not feasible, and it was difficult to find a reliable biological model to test our vaccine formulation, we reproduced entirely the study using the 19-kDa C-terminal region of MSP-1 from *P. falciparum.*This region of MSP-1, termed PfMSP1~19~, was selected because it has been extensively studied as a vaccine candidate, as described above. Rabbits injected with PfMSP1~19~ fused to flagellin raised high antibody titres that dramatically inhibited the *in vitro* growth of the parasite lines 3D7, S20, and FCR3 \[[@B86]\]. A similar approach is now being used to generate recombinant fusion proteins containing immuno-dominant epitopes of the sporozoite stage CS protein.

Using another approach, we inserted the CS protein CD8^+^ T-cell epitope CS~280--288~) from the murine malaria parasite *P. yoelii* into the central hypervariable (D3) domain of the *S.*Muenchen FliC flagellin \[[@B74]\]. The flagellin adjuvant effects were determined with two vaccine formulations: (i) attenuated *S.*Dublin strains administered orally expressing hybrid flagella composed of the flagellin-CS fusion protein and (ii) purified flagellins administered s.c. to mice either as hybrid flagellin or native flagellin mixed with synthetic CS~280--288~ peptide. Both formulations induced CS-specific CD8^+^ T-cell responses in the absence of any conventional adjuvant, as measured by ELISPOT \[[@B87]\]. These results suggest that *Salmonella* flagellins are promising soluble adjuvants for synthetic peptides in regard to the activation of specific cytotoxic T cell responses.

To our knowledge, these were the first reports of an induction of specific humoral and cellular immune responses in experimental immunisations with recombinant proteins based on malaria vaccine antigens without the addition of any conventional adjuvant. As mentioned above, the magnitude of an immune response induced against recombinant proteins is highly dependent on the potency of the adjuvant formulation.

4. Adjuvanticity Mechanism of Flagellin {#sec4}
=======================================

The mechanisms by which flagellin acts as an adjuvant are not fully understood, but it is likely to be dependent on direct APC activation, especially DC activation, to enhance antigen presentation. Flagellin up-regulates the expression of costimulatory molecules such as B7-1, B7-2, and CD40 in murine bone marrow-derived DCs \[[@B88], [@B89]\] and B7-1, B7-2, CD83, and CCR7 in human primary blood DCs \[[@B62]\]. Moreover, flagellin-maturated human DCs down-regulate endocytic activity, a hallmark of DC activation, and they have enhanced T-cell stimulatory activity \[[@B62]\]. Another remarkable capacity of flagellin is to convert tolerogenic DCs into activated antigen-presenting cells, which is an unusual ability \[[@B90]\]. The effects of flagellin on DCs are at least in part dependent on TLR5 activation, as evidenced by the fact that OVA-specific CD4^+^ T cell proliferation in response to immunisation with flagellin-OVA is impaired by depletion of TLR5^+/+^CD11c^+/+^ cells or in TLR5^−/−^) mice \[[@B67]\]. However, TLR5^−/−^) mice still develop strong antiflagellin antibody responses after injection of flagellin; in addition, MyD88^−/−^) mice, which have impaired TLR- and NOD-dependent signalling, respond to flagellin injection with less robust antibody production \[[@B91]\]. In fact, recent results have shown that both TLR5 and NOD-like receptors operate in a complementary manner to support the flagellin adjuvant effects, at least in relation to the induction of humoral responses \[[@B92]\].

The requirement for the physical linking of flagellin to the antigen is still a matter of debate. The fusion requirement may be dependent on the amount of antigen injected. One possibility is that when flagellin is bound to the antigen, there is concomitant APC activation and antigen uptake, as opposed to coadministered soluble antigen and flagellin when an activated APC may not uptake the antigen at the same time of activation. The fact that activated DCs down-regulate endocytic activity supports this hypothesis, indicating that if activation does not happen in the presence of the antigen, uptake may be impaired, and more antigen would be required to increase the chance of concomitant antigen uptake and APC activation. In fact, when we tested equimolar amounts of flagellin and antigen that were fused or co-administered, we found that the responses are comparable in the range of 10 *μ*g; however, the fusion protein was more efficient in the induction of antigen-specific antibody responses at the levels of 1 *μ*g or 0.1 *μ*g (Bargieri DY and Rodrigues MM, unpublished data).

5. Conclusions {#sec5}
==============

RTS,S is arguably the most advanced vaccine against *P. falciparum* malaria. Its development provided great lessons; for example, we learned that the delivery system/adjuvant is integral for the induction of any degree of immunity against malaria. Despite the on-going RTS,S Phase III clinical trials, we should not stop looking for new methods to improve the immunogenicity of recombinant antigens in humans. One possibility would be to add other recombinant vectors, such as adenoviral vectors, in combination with RTS,S to boost its potency. In this paper, we proposed an alternative approach that involved the structural modification of malarial antigens to increase their intrinsic immunogenicity. The use of recombinant fusion flagellins containing malarial epitopes may be a simple and inexpensive way to enhance protein antigenicity. The fact that recombinant flagellins have reached Phase I/II clinical trials should accelerate further studies in this direction.
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